Serum miRNA signature in moyamoya disease

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Dai, Dongwei ^a   Lu, Qiong ^a   Huang, Qinghai ^a   Yang, Pengfei ^a   Hong, Bo ^a   Xu, Yi ^a   Zhao, Wenyuan ^a   Liu, Jianmin ^a   Li, Qiang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 101; MICRORNA 103; MICRORNA 106B; MICRORNA 1182; MICRORNA 1183; MICRORNA 122; MICRORNA 125A 3P; MICRORNA 126; MICRORNA 1290; MICRORNA 130A; MICRORNA 144; MICRORNA 146A; MICRORNA 15A; MICRORNA 15B; MICRORNA 185; MICRORNA 19B; MICRORNA 23A; MICRORNA 26A; MICRORNA 30A; MICRORNA 30E; MICRORNA 320E; MICRORNA 4313; MICRORNA 4826; MICRORNA 557; MICRORNA 601; MICRORNA 720; MICRORNA 92A; UNCLASSIFIED DRUG; BRCC3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; RNF213 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTOME; UBIQUITIN PROTEIN LIGASE;

ADULT; ANGIOGENESIS; ARTICLE; AUTOPHAGY; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; MALE; MICROARRAY ANALYSIS; MOYAMOYA DISEASE; PATHOGENESIS; PROGNOSIS; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; UPREGULATION; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MALE; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; MOYAMOYA DISEASE; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 84905493070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102382     Document Type: Article

References (58)

1. Weinberg DG, Arnaout OM, Rahme RJ, Aoun SG, Batjer HH, et al. (2011) Moyamoya disease: a review of histopathology, biochemistry, and genetics. Neurosurg Focus 30: E20.
2. Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7: 1056-1066
3. Chen J, Liu J, Duan L, Xu R, Han YQ, et al. (2013) Impaired dynamic cerebral autoregulation in moyamoya disease. CNS NeurosciTher 19: 638-640
4. Dai DW, Zhao WY, Zhang YW, Yang ZG, Li Q, et al. (2013) Role of CT perfusion imaging in evaluating the effects of multiple burr hole surgery on adult ischemic Moyamoya disease. Neuroradiology. 55: 1431-1438.
5. Lu CF, Guo WY, Chang FC, Huang SR, Chou YC, et al. (2013) Hemodynamic segmentation of brain perfusion images with delay and dispersion effects using an expectation-maximization algorithm. PLoS One 8:e68986.
6. Maeda M, Tsuchida C (1999) "Ivy sign" on fluid-attenuated inversion-recovery images in childhood moyamoya disease. Am J Neuroradiol 20: 1836-1838.
7. Mori N, Mugikura S, Higano S, Kaneta T, Fujimura M, et al. (2009) The leptomeningeal "ivy sign" on fluid-attenuated inversion recovery MR imaging in Moyamoya disease: a sign of decreased cerebral vascular reserve? Am J Neuroradiol 30: 930-935.
8. Kim YJ, Lee DH, Kwon JY, Kang DW, Suh DC, et al. (2013) High resolution MRI difference between moyamoya disease and intracranial atherosclerosis. Eur J Neurol 20: 1311-1318.
9. Yun TJ, Sohn CH, Han MH, Kang HS, Kim JE, et al. (2013) Effect of Delayed Transit Time on Arterial Spin Labeling: Correlation With Dynamic Susceptibility Contrast Perfusion Magnetic Resonance in Moyamoya Disease. Invest Radiol 48: 795-802.
10. Duan L, Bao XY, Yang WZ, Shi WC, Li DS, et al. (2012) Moyamoya disease in China: its clinical features and outcomes. Stroke 43: 56-60.
11. Kossorotoff M, Herve D, Toulgoat F, Renaud C, Presles E, et al. (2012) Paediatric moyamoya in mainland France: a comprehensive survey of academic neuropaediatric centres. Cerebrovasc Dis 33: 76-79.
12. Li H, Zhang ZS, Liu W, Yang WZ, Dong ZN, et al. (2010) Association of a functional polymorphism in the MMP-3 gene with Moyamoya Disease in the Chinese Han population. Cerebrovasc Dis 30: 618-625.
13. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, et al. (2004) A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49: 278-281. (Pubitemid 38856021)
14. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, et al. (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31: 930-935. (Pubitemid 30198441)
15. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, et al. (2009) Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84: 617-627.
16. Liu W, Hashikata H, Inoue K, Matsuura N, Mineharu Y, et al. (2010) A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians. Environ Health Prevent Med 15: 94-104.
17. Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, et al. (2010) Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir: 1-8.
18. Wu Z, Jiang H, Zhang L, Xu X, Zhang X, et al. (2012) Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One. 7:e48179.
19. Hitomi T, Habu T, Kobayashi H, Okuda H, Harada KH, et al. (2013) Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. BiochemBiophys Res Commun. 438: 13-19.
20. Wang X, Zhang Z, Liu W, Xiong Y, Sun W, et al. (2013) Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene. 526: 437-442
21. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, et al. (2010) A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56: 34-40.
22. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, et al. (2011) Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. Plos ONE 6: e22542.
23. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13: e249-258.
24. Shi L, Cheng Z, Zhang J, Li R, Zhao P, et al. (2008) hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236: 185-193.
25. Wang Y, Wang X, Zhang J, Sun G, Luo H, et al. (2012) MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol 106: 217-224.
26. Bai J, Guo A, Hong Z, Kuai W (2012) Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 5: 213-219.
27. Boeri M, Verri C, Conte D, Roz L, Modena P, et al. (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 108: 3713-3718.
28. Brase JC, Wuttig D, Kuner R, Sultmann H (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9: 306.
29. Zhao C, Dong J, Jiang T, Shi Z, Yu B, et al. (2011) Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One 6: e23925.
30. Dai DW, Lu Q, Wang LX, Zhao WY, Cao YQ, et al. (2013)Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer. 13: 478.
31. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, et al. (2010) Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 3: 109-113.
32. Wang J, Chen J, Chang P, LeBlanc A, Li D, et al. (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2: 807-813.
33. Kraemer M, Heienbrok W, Berlit P (2008) Moyamoya disease in Europeans. Stroke. 39: 3193-200.
34. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, et al. (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666.
35. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al.(2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105: 10513-8.
36. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR), Methods. 50: 298-301
37. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. Nat Genet 25: 25-29. (Pubitemid 30257031)
38. Kanehisa M (2013) Molecular network analysis of diseases and drugs in KEGG. Methods Mol Biol 939: 263-275.
39. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular datasets. Nucleic Acids Res 40: D109-D114.
40. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57
41. Wang X, Cao L, Wang Y, Liu N, You Y (2012) Regulation of let-7 and its target oncogenes (Review). Oncol Lett 3: 955-960.
42. Concepcion CP, Bonetti C, Ventura A (2012) The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J 18: 262-267.
43. Aqeilan RI, Calin GA, Croce CM (2010) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
44. Liu Z, Yang D, Xie P, Ren G, Sun G, et al. (2012) MiR-106b and MiR-15b modulate apoptosis and angiogenesis in myocardial infarction. Cell Physiol Biochem 29: 851-862.
45. Taurino C, Miller WH, McBride MW, McClure JD, Khanin R, et al. (2010) Gene expression profiling in whole blood of patients with coronary artery disease. Clin Sci (Lond) 119: 335-343.
46. Wu WH, Hu CP, Chen XP, Zhang WF, Li XW, et al. (2011) MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension. Am J Hypertens 24: 1087-1093.
47. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, et al. (2012) Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 107: 700-706.
48. Li D, Yang P, Xiong Q, Song X, Yang X, et al. (2010) MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J Hypertens 28: 1646-1654.
49. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, et al. (2010) Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 81: 673-678.
50. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, et al. (2011) Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6: e22542.
51. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, et al. (2011) A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56: 34-40.
52. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, et al. (2012) Homozygous c.14576G.A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 78: 803-810.
53. Miskinyte S, Butler MG, Herve D, Sarret C, Nicolino M, et al. (2011) Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet 88: 718-728.
54. Scholer N, Langer C, Dohner H, Buske C, Kuchenbauer F (2010) Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 38: 1126-1130.
55. Long G, Wang F, Duan Q, Chen F, Yang S, et al. (2012) Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci 8: 811-818.
56. Bi Q, Tang S, Xia L, Du R, Fan R, et al. (2012) Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 7: e40169.
57. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285: 17442-17452.
58. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.